Fisher B, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20(20):4141–9. https://doi.org/10.1200/JCO.2002.11.101.

Article  CAS  PubMed  Google Scholar 

G Early Breast Cancer Trialists’ Collaborative, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2.

Article  Google Scholar 

Whelan TJ, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513–20. https://doi.org/10.1056/NEJMoa0906260.

Article  CAS  PubMed  Google Scholar 

Haviland JS, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086–94. https://doi.org/10.1016/S1470-2045(13)70386-3.

Article  PubMed  Google Scholar 

ST Group, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331–41. https://doi.org/10.1016/S1470-2045(08)70077-9.

Article  Google Scholar 

ST Group, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet. 2008;371(9618):1098–107. https://doi.org/10.1016/S0140-6736(08)60348-7.

Article  Google Scholar 

Offersen BV, et al. Hypofractionated versus standard fractionated radiotherapy in patients with early breast cancer or ductal carcinoma in situ in a randomized phase III trial: the DBCG HYPO trial. J Clin Oncol. 2020;38(31):3615–25. https://doi.org/10.1200/JCO.20.01363.

Article  PubMed  Google Scholar 

Amin MB, Edge SB, Greene FL, et al. editors. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017

Sasaoka M, Futami T. Dosimetric evaluation of whole breast radiotherapy using field-in-field technique in early-stage breast cancer. Int J Clin Oncol. 2011;16(3):250–6. https://doi.org/10.1007/s10147-010-0175-1.

Article  PubMed  Google Scholar 

Fournier-Bidoz N, Kirova YM, Campana F, Dendale R, Fourquet A. Simplified field-in-field technique for a large-scale implementation in breast radiation treatment. Med Dosim. 2012;37(2):131–7. https://doi.org/10.1016/j.meddos.2011.03.002.

Article  PubMed  Google Scholar 

Friend M, MELBOURNE/AU. An overview of Electronic tissue Compensation (ECOMP) for breast Radiotherapy. In: European Society of Radiology. 2014. https://doi.org/10.1594/ranzcr2014/R-0170. [Online]. Available: https://epos.myesr.org/poster/ranzcr/ranzcr2014/R-0170/Methods%20and%20materials#poster. Accessed 11 Nov 2024.

Kuwahata N, Fujita H, Yamanishi H, Okazaki E, Fukuda H. Dosimetric comparison of irregular surface compensator and field-in-field for whole breast radiotherapy. J Med Phys. 2018;43(2):79–84. https://doi.org/10.4103/jmp.JMP_73_17.

Article  PubMed  PubMed Central  Google Scholar 

Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of secondary malignancies after radiation therapy for breast cancer: comprehensive results. Breast. 2017;35:122–9. https://doi.org/10.1016/j.breast.2017.07.004.

Article  PubMed  Google Scholar 

Smith BD, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol. 2018;8(3):145–52. https://doi.org/10.1016/j.prro.2018.01.012.

Article  PubMed  Google Scholar 

Romestaing P, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997;15(3):963–8. https://doi.org/10.1200/JCO.1997.15.3.963.

Article  CAS  PubMed  Google Scholar 

Bartelink H, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881–10882 trial. J Clin Oncol. 2007;25(22):3259–65. https://doi.org/10.1200/JCO.2007.11.4991.

Article  PubMed  Google Scholar 

Coles CE, et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet. 2023;401(10394):2124–37. https://doi.org/10.1016/S0140-6736(23)00619-0.

Article  PubMed  Google Scholar 

Forster T, et al. Quality of life after simultaneously integrated boost with intensity-modulated versus conventional radiotherapy with sequential boost for adjuvant treatment of breast cancer: 2-year results of the multicenter randomized IMRT-MC2 trial. Radiother Oncol. 2021;163:165–76. https://doi.org/10.1016/j.radonc.2021.08.019.

Article  PubMed  Google Scholar 

Unterkirhere O, et al. Single-institution prospective evaluation of moderately hypofractionated whole-breast radiation therapy with simultaneous integrated boost with or without lymphatic drainage irradiation after breast-conserving surgery. Adv Radiat Oncol. 2023;8(6):101270. https://doi.org/10.1016/j.adro.2023.101270.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Vicini F, et al. NRG RTOG 1005: A phase III trial of hypo fractionated whole breast irradiation with concurrent boost vs. conventional whole breast irradiation plus sequential boost following lumpectomy for high risk early-stage breast cancer. In: ASTRO Annual Meeting. Int J Radiat Oncol Biol Phys. 2022;114(3):S1.

Article  Google Scholar 

Gentilini O, et al. Ipsilateral axillary recurrence after breast conservative surgery: the protective effect of whole breast radiotherapy. Radiother Oncol. 2017;122(1):37–44. https://doi.org/10.1016/j.radonc.2016.12.021.

Article  PubMed  Google Scholar 

Whelan TJ, Olivotto IA, Levine MN. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(19):1878–9. https://doi.org/10.1056/NEJMc1510505.

Article  PubMed  Google Scholar 

Poortmans PM, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317–27. https://doi.org/10.1056/NEJMoa1415369.

Article  CAS  PubMed  Google Scholar 

Poortmans PM, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I-III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21(12):1602–10. https://doi.org/10.1016/S1470-2045(20)30472-1.

Article  PubMed  Google Scholar 

Mamounas E, Bando H, White J. GS02–07 Loco-regional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant chemotherapy: primary outcomes of NRG Oncology/NSABP B-51/RTOG 1304. In: San Antonio breast cancer Symposium. 2023.

Owen JR, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7(6):467–71. https://doi.org/10.1016/S1470-2045(06)70699-4.

Article  PubMed  Google Scholar 

Yarnold JR, Brunt AM, Chatterjee S, Somaiah N, Kirby AM. From 25 fractions to five: how hypofractionation has revolutionised adjuvant breast radiotherapy. Clin Oncol (R Coll Radiol). 2022;34(5):332–9. https://doi.org/10.1016/j.clon.2022.03.001.

Article  CAS  PubMed  Google Scholar 

FT Group, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother Oncol. 2011;100(1):93–100. https://doi.org/10.1016/j.radonc.2011.06.026.

Article  Google Scholar 

Brunt AM, et al. Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer. J Clin Oncol. 2020;38(28):3261–72. https://doi.org/10.1200/JCO.19.02750.

Article  PubMed  PubMed Central  Google Scholar 

Brunt AM, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother Oncol. 2016;120(1):114–8. https://doi.org/10.1016/j.radonc.2016.02.027.

Article  PubMed  PubMed Central  Google Scholar 

Murray Brunt A, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet. 2020;395(10237):1613–26. https://doi.org/10.1016/S0140-6736(20)30932-6.

Article  PubMed  PubMed Central  Google Scholar 

Lewis P, et al. Moving forward fast with FAST-Forward. Clin Oncol (R Coll Radiol). 2021;33(7):427–9. https://doi.org/10.1016/j.clon.2021.04.007.

Article  CAS  PubMed  Google Scholar